Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Trevisan B, Pepe FF, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V, Cazzaniga ME; VICTOR Study Group. Trevisan B, et al. Among authors: butera a. Sci Rep. 2023 Jul 28;13(1):12255. doi: 10.1038/s41598-023-39386-x. Sci Rep. 2023. PMID: 37507480 Free PMC article.
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group. Cazzaniga ME, et al. Among authors: butera a. Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22. Breast. 2019. PMID: 31470257
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, Torri V; VICTOR Study Group. Cazzaniga ME, et al. Among authors: butera a. Breast Cancer Res Treat. 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21. Breast Cancer Res Treat. 2021. PMID: 34546500 Free PMC article.
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M. Adamo V, et al. Among authors: butera a. Ther Adv Med Oncol. 2019 Dec 19;11:1758835919895755. doi: 10.1177/1758835919895755. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31903098 Free PMC article.
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists.
Blasi L, Bordonaro R, Borsellino N, Butera A, Caruso M, Cordio S, Liborio DC, Ferraù F, Giuffrida D, Parra HS, Spada M, Tralongo P, Valenza R, Verderame F, Vitello S, Zerilli F, Piazza D, Firenze A, Gebbia V. Blasi L, et al. Among authors: butera a. Ecancermedicalscience. 2020 May 15;14:1046. doi: 10.3332/ecancer.2020.1046. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32565899 Free PMC article.
Cancer patient-centered home care: a new model for health care in oncology.
Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V. Tralongo P, et al. Among authors: butera a. Ther Clin Risk Manag. 2011;7:387-92. doi: 10.2147/TCRM.S22119. Epub 2011 Sep 9. Ther Clin Risk Manag. 2011. PMID: 21941445 Free PMC article.
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Rosati G, et al. Among authors: butera a. Invest New Drugs. 2012 Oct;30(5):1978-83. doi: 10.1007/s10637-011-9721-6. Epub 2011 Jul 19. Invest New Drugs. 2012. PMID: 21769636 Clinical Trial.
133 results